Summary
The effect of a high-fat meal on the pharmacokinetics of mirtazapine was studied in 19 healthy normal young male volunteers. In a randomized two-period crossover study, each volunteer received an oral dose of 15 mg of mirtazapine in the form of tablets, in the fasting state and after a high-fat meal, with a washout period of 14 days between the two doses. Serial blood samples were taken and pharmacokinetic parameters calculated and statistically analyzed from mirtazapine plasma levels.
The extent of absorption of mirtazapine, as measured by the area under the plasma level versus time curve, was found to be equivalent for the fasting and the fed state. Food intake was shown to have no influence on the elimination of mirtazapine, as measured by its elimination half-life.
The rate of mirtazapine absorption, as measured by the peak level (Cmax), was not altered by food. The peak time (tmax), however, in subjects in the fed state showed an increase: the 90%-confidence interval for the median difference ranged from 0.25 to 1.25 h. This was the only effect of food found in this study. It is considered to be of no clinical consequence.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
De Boer T., Nefkens F., Van Helvoirt A. (1994): The α2 antagonist Org 3770 enhances serotonin transmission in vivo. Eur. J. Pharmacol., 253, R5-R6.
De Boer T., Ruigt G.S.F. (1995): The selective α2-adrenoreceptor antagonist Org 3770 (mirtazapine) enhances noradrenergic and serotonin1A-mediated serotonergic neurotransmission. CNS Drugs, 4 (Suppl 1), 29–38.
De Montigny C., Haddjeri N., Mongeau R., Blier P. (1995): The effects of mirtazapine on interactions between central noradrenergic and serotonergic systems. CNS Drugs, 4 (Suppl 1), 13–17.
De Boer T., Maura G., Raiteri M., De Vos C.J., Wieringa J., Pinder R.M. (1988): Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of minaserin, Org 3770 and its enantiomers. Neuropharmacology, 27, 399–408.
Bremner J.D. (1995): A double-blind comparison of Org 3770, amitriptyline and placebo in major depression. J. Clin. Psychiatry, 56, 519–525.
Claghorn J.L., Lessem M.D. (1995): A double-llind placebo controlled study of Org 3770 in depressed outpatients. J. Affect. Disord., 34, 165–171.
Sitsen J.M.A., Zivkov M., Dieterle D. (1995): Wirksamkeit und Verträglichkeit von Org 3770 bei Patienten mit einer Major Depression. Psychopharmakotherapie, 2, 68–71.
Kahn M.C. (1995): A randomised, double-blind, placebo-controlled, 5-weeks’ study of Org 3770 (mirtazapine) in major depression. Hum. Psychopharmacol., 10, (Suppl 2), S119-S124.
Van Moffaert M., De Wilde J., Vereecken A. et al. (1995): Mirtazapine is more effective than trazodone. A controlled study in hospitalised patients with major depression. Int. Clin. Psychopharmacol., 10, 3–9.
Mullin J., Lodge A., Bennie E., McCreadie R., Bhatt G.S., Fenton G. (1997): A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J. Psychopharmacol., In press.
Zivkov M., De Jongh G. (1995): Org 3770 vs amitriptyline; a 6-week, randomised double-blind multicentre trial in hospitalised patients. Hum. Psychopharmacol., 10, 263–271.
Richou H., Ruimy P., Charbaut J. et al. (1995): A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum. Psychopharmacol., 10, 263–271.
Marttilla M., Jääskeläinen J., Järvi R. et al. (1995): A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur. Neuropsychopharmacol., 5, 441–446.
Zivkov M., Roes K.C.B., Pols A.G. (1995): Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: a meta-analysis. Hum. Psychopharmacol., 10 (Suppl 2), S135-S145.
Halikas J.A. (1995): Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum. Psychopharmacol., 10 (Suppl 2), S125-S133.
Hoyberg O.J., Maragakis B., Mullin J. et al. (1997). A double blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr. Scand., In press.
Voortman G., Paanakker J.E. (1995): Bioavailability of mirtazapine from Remeron® tablets after single and multiple oral dosing. Hum. Psychopharmacol., 10 (Suppl 2), S83-S96.
Timmer C.J., Lohmann A., Mink C.P.A. (1995): Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron® tablets. Hum. Psychopharmacol., 10, (Suppl 2), S97-S106.
Timmer C.J., Paanakker J.E., Van Hal H.J.M. (1996): Pharmacokinetics of mirtazapine from orally administered tablets; influence of gender, age and treatment regimen. Hum. Psychopharmacol., In press.
Kaspersen F.M., Van Rooij A.A.M., Sperling E.G.M., Wieringa J.H. (1989): The synthesis of Org 3770 labelled with3H,13C and14C. J. Labelled Compounds Radiopharmaceut., 27, 1055–1068.
Paanakker J.E., Van Hal H.J.M. (1987): Capillary gas chromatographic assay for the routine monitoring of the antidepressant mepirzepine in human plasma. J. Chromatogr. Biomed. Appl., 417, 203–207.
SAS Institute Inc., (1989): SAS User’s Guide, Version 6.06. Cary, NC, USA: SAS Institute Inc.
US Food and Drug Administration Guidance (1992): Statistical procedures for bioequivalence testing using a standard two-treatment cross-over design. Statement prepared by the Division of Bioequivalence, Office of Generic Drugs of the FDA, informal communication under 21 CFR 10.90.
Commission on the European Communities, Committee for Proprietary Medicinal Products CPMP. Note for Guidance, Investigation of Bioavailability and Bioequivalence, III/54/89-EN.
Wijnand H.P. (1993): Bioequivalence revisited — non-parametric analysis of two-period cross-over studies. Computer Methods Progr. Biomed., 49, 249–259.
Schuirmann D.J. (1987): A comparison of the two one-sided tests procedure and the power approach for testing equivalence in bioequivalence assessment. J. Pharmacokinet. Biopharm., 15, 657–680.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cohen, M., Panagides, J., Timmer, C.J. et al. Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal. European Journal of Drug Metabolism and Pharmacokinetics 22, 103–110 (1997). https://doi.org/10.1007/BF03189792
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03189792